MedTrace Logo

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

NCT02378922 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-12-27

No results posted yet for this study

Summary

This clinical trial studies gene-modified, human immunodeficiency virus (HIV)-protected stem cell transplant in treating patients with HIV-associated lymphoma. Stem cells, or cells which help form blood, are collected from the patient and stored. They are treated in the laboratory to help protect the immune system from HIV. Chemotherapy is given before transplant to kill lymphoma cells and to make room for new stem cells to grow. Patients then receive the stem cells that were collected from them before chemotherapy and have been genetically modified to replace the stem cells killed by the chemotherapy.

Conditions

  • AIDS-Related Hodgkin Lymphoma
  • AIDS-Related Non-Hodgkin Lymphoma
  • HIV Infection
  • Recurrent Hodgkin Lymphoma
  • Recurrent Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL

Gene-Modified HIV-Protected Hematopoietic Stem Cells

Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Transplant Conditioning

Undergo high-dose chemotherapy or chemoradiotherapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Hans-Peter Kiem · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
66 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-22
Primary Completion
2019-06-15
Completion
2019-06-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02378922 on ClinicalTrials.gov